Floatz Rating
B59/100
Confidence
Indicative
Sponsor
University Eye Hospital, Freiburg
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01962571CT.gov Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Optic Neuritis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Erythropoietin Alfa (this asset) | University Eye Hospital, Freiburg | P3 | B · 59 |
| Interferon ?1 (Human Fibroblast Protein Moiety) | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | P4 | BB |
| Fampridine | Courtney Casserly | P2/3 | BB |
| Privosegtor | Oculis | P3 | B |
| Simvastatin | Glostrup University Hospital, Copenhagen | P3 | B |
| Methotrexate | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | P4 | B |
| Prednisone | National Eye Institute (NEI) | P3 | B |
| Erythropoietin | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | P2 | B |
| Amiloride | University of Oxford | P2 | B |
+7 more in the Optic Neuritis cohort
Other indications for Erythropoietin Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anemia | — | P3 | B · 57 |
| Ovarian Cancer | — | P3 | NR |
| Ovarian Carcinoma | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Interferon ?1 (Human Fibroblast Protein Moiety)MidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteBB
- FampridineCourtney CasserlyBB
- PrivosegtorOculisB
- SimvastatinGlostrup University Hospital, CopenhagenB
- MethotrexateMidAmerica Neuroscience Research Foundation at Rowe Neurology InstituteB
Citation
Floatz Terminal. Erythropoietin Alfa in Optic Neuritis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/erythropoietin-alfa-optic-neuritis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →